



# Intercytex

## Executive Management Team



Nick Higgins BSc, MSc



Max Herrmann BSc, ACA



Paul Kemp BSc, PhD



John St Clair Roberts  
MRCS, LRCP, FFPM



John Lovelady BSc, PhD

### Nick Higgins BSc, MSc

Chief Executive Officer and Executive Director

Nick joined Intercytex as Chief Executive Officer in January 2005 having been a Non-Executive Director of the company since it was founded, and brings over 20 years of experience in commercialising biotechnology products. He was previously Chief Business Officer and a Board Director of Acambis plc (vaccines) which he joined in 1994. He was responsible for all commercial activities including IP management, licensing, corporate development, mergers/acquisitions and sales and marketing. In addition, he played a key role in the company's flotation on the London Stock Exchange in 1995.

Prior to Acambis he worked for Porton International Ltd (biologicals) where he managed IP and commercial agreements with the company's collaborators. Before Porton he worked for The PA Consultancy Group where he was a founder member of the Biotechnology Group in which he participated in over 50 European and international assignments. He started his business career with Unilever Research Ltd (consumer goods) as a chemical and biochemical engineer. Nick has a BSc in biochemistry from the University College of Wales, an MSc in biochemical engineering from University College, London and an MSc in the Management of Intellectual Property from QMW, London.

### Max Herrmann BSc, ACA

Chief Financial Officer and Executive Director

Max joined Intercytex as Chief Financial Officer in September 2008. Previously he was a consultant for Fusion IP plc (an investor in science and technology) and Managing Director of ING Equity Markets where he managed a team of analysts and a specialist sales force covering the European pharmaceutical, biotechnology and healthcare sectors. Prior to ING, he was a pharmaceutical analyst at Robert Fleming Securities. Max started his industry career as financial controller for Onyx Pharmaceuticals, a US-quoted drug development company, where he was integral to its successful listing on NASDAQ. Max has a BSc (Hons) in microbiology from the University of Kent, and qualified as a Chartered Accountant with Arthur Andersen.

### Paul Kemp BSc, PhD

Founder, Chief Scientific Officer and Executive Director

Paul founded Intercytex in 1999 and is its Chief Scientific Officer. He has over 17 years of experience in the commercial development of cell therapies. Prior to founding Intercytex, he was VP Research at Organogenesis Inc. He joined the founders in 1987 as a staff scientist researching into collagen as part of the wound repair stimulant programme Apligraf® and he was later instrumental in its development, manufacture and methods of shipping. He is a principal inventor on several patents related to various regenerative medicines. Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.

### John St Clair Roberts MRCS, LRCP, FFPM

Vice President - Clinical and Regulatory Affairs

John joined Intercytex as VP Clinical and Regulatory Affairs in September 2005 with over 20 years of experience in the clinical development of vaccines and biological products. Previously, he held the position of Medical Director at a number of leading biotechnology companies including Microscience plc, Xenova Group plc, Cantab Pharmaceuticals plc and Merieux UK.

John graduated in medicine from the Royal College of Surgeons in Ireland and prior to his career in industry, he practised hospital medicine for a number of years in the National Health Service (UK). John has contributed to numerous publications, presentations, technical committees and lectures.

John was elected a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK) in 1999 and is a Fellow of the Royal Society of Medicine and the Medical Society of London. He is also a Member of the British Association of Pharmaceutical Physicians, the British Medical Association and the Medico-Legal Society.

### John Lovelady BSc, PhD

Vice President - Operations

John joined Intercytex in April 2007 with over 20 years of experience in the production of biologicals, the management of GMP facilities, QA/QC and regulatory compliance. He was previously Director of GMP Manufacturing Operations at Cobra Biomanufacturing plc, a contract manufacturer of clinical grade proteins, DNA and viruses. Prior to Cobra he was an independent consultant to the industry, VP of Technical R&D and Manufacturing at Centelion (formerly Gencell, a Paris-based, French biopharmaceutical/gene therapy company spun out from Aventis), VP Operations at Genzyme Corporation (UK subsidiary of a US biotechnology company), Fermentation Manager at Fermentech Ltd (a private fermentation facility) and he started his career as a research scientist at Technoform Developments Ltd (Porton Down).

John has a BSc in Applied Biology and a PhD in enzyme biosynthesis.

### Contact:

Intercytex, Innovation House, Crewe Road, Manchester M23 9QR United Kingdom

T +44 (0)161 904 4500 F +44 (0)161 904 4510 [mail@intercytix.com](mailto:mail@intercytix.com) [www.intercytix.com](http://www.intercytix.com)



# Intercytex

## Board of Directors



Ian Kent



John Aston MA, ACA



Alan Suggett  
BSc, PhD, CChem, FRSC



Nick Higgins BSc, MSc



Max Herrmann BSc, ACA



Paul Kemp BSc, PhD

### Ian Kent

#### Non-Executive Chairman

Ian Kent joined Intercytex as Non-Executive Chairman in September 2001. He brings significant experience to Intercytex having been Chairman and Non-Executive Director of a number of successful public and private life sciences companies. He is currently Chairman of venture capital backed Argenta Discovery Ltd (respiratory drug discovery). He was Founder, Chairman and Executive Director of Imutran Ltd (xenotransplantation) which was sold to Novartis in 1997. He was Chairman of Innovata plc which was sold to Vectura Group plc in 2007 and Plarmed, sold to Roche in 2008. His previous Non-Executive appointments include Vernalis plc (drug discovery and development), Biofocus plc (preclinical drug discovery), Adprotech Ltd (protein therapeutics), LGC Holdings (diagnostic services) and Roslin Biomed Ltd (cloning).

He is Chairman of Intercytex' Remuneration Committee and a member of the Audit and Nominations Committees.

### John Aston MA, ACA

#### Non-Executive Director

John Aston joined Intercytex as a Non-Executive Director in July 2005. He brings over 20 years of biotech financing and investment banking experience to the role. He is currently Chief Financial Officer of Astex Therapeutics Ltd, a privately owned UK drug discovery and development company. He was previously Chief Financial Officer of Cambridge Antibody Technology Group, a UK biopharmaceutical company. John joined CAT as CFO in 1996 and took the company through a successful flotation on the London Stock Exchange in 1997, an international financing raising over £90 million in March 2000, a US Listing on the NASDAQ National Market in 2001 and finally, its acquisition by AstraZeneca in 2006. Prior to CAT, John was a Director in Corporate Finance at J. Henry Schroder & Co Ltd where he worked for 14 years. He qualified as a chartered accountant with Price Waterhouse and also worked at the British Technology Group.

He is Chairman of Intercytex' Audit Committee and a member of its Nominations and Remuneration Committees.

### Alan Suggett BSc, PhD, CChem, FRSC

#### Non-Executive Director

Alan Suggett joined Intercytex as a Non-Executive Director in June 2005. He brings 20 years of experience of operating at the technical/business interface in the medical devices field and in strategic and governance leadership, in particular related to R&D, clinical, regulatory, and environmental aspects. Moreover, as an early industrial champion of tissue and cell engineering he has direct experience of the challenges involved in bringing such technologies into clinical practice.

Until retiring from his full-time operational roles at the beginning of 2004, he was Group Director of Technology at Smith & Nephew plc and a long-standing member of the Company's Executive Committee. Previously he was Group R&D Director at Smith & Nephew and held senior positions with Scottish & Newcastle Breweries and Unilever Research.

He is Chairman of the Medical Devices Faraday Partnership and the Scientific Advisory Board of Photopharmica Limited, a Fellow of the Royal Society of Chemistry and an Honorary Visiting Professor at the University of York. He is Chairman of Intercytex' Nominations Committee and a member of the Audit and Remuneration Committees.

### Nick Higgins BSc, MSc

#### Chief Executive Officer and Executive Director

Nick joined Intercytex as Chief Executive Officer in January 2005 having been a Non-Executive Director of the company since it was founded, and brings over 20 years of experience in commercialising biotechnology products.

He was previously Chief Business Officer and a Board Director of Acambis plc (vaccines) which he joined in 1994. He was responsible for all commercial activities including IP management, licensing, corporate development, mergers/acquisitions and sales and marketing. In addition, he played a key role in the company's flotation on the London Stock Exchange in 1995. Prior to Acambis he worked for Porton International Ltd (biologicals) where he managed IP and commercial agreements with the company's collaborators.

Before Porton he worked for The PA Consultancy Group where he was a founder member of the Biotechnology Group in which he participated in over 50 European and international assignments. He started his business career with Unilever Research Ltd (consumer goods) as a chemical and biochemical engineer. Nick has a BSc in biochemistry from the University College of Wales, an MSc in biochemical engineering from University College, London and an MSc in the Management of Intellectual Property from QMW, London.

### Max Herrmann BSc, ACA

#### Chief Financial Officer and Executive Director

Max joined Intercytex as Chief Financial Officer in September 2008. Previously he was a consultant for Fusion IP plc (an investor in science and technology) and Managing Director of ING Equity Markets where he managed a team of analysts and a specialist sales force covering the European pharmaceutical, biotechnology and healthcare sectors. Prior to ING, he was a pharmaceutical analyst at Robert Fleming Securities. Max started his industry career as financial controller for Onyx Pharmaceuticals, a US-quoted drug development company, where he was integral to its successful listing on NASDAQ. Max has a BSc (Hons) in microbiology from the University of Kent, and qualified as a Chartered Accountant with Arthur Andersen.

### Paul Kemp BSc, PhD

#### Founder, Chief Scientific Officer and Executive Director

Paul founded Intercytex in 1999 and is its Chief Scientific Officer. He has over 17 years of experience in the commercial development of cell therapies. Prior to founding Intercytex, he was VP Research at Organogenesis Inc. He joined the founders in 1987 as a staff scientist researching into collagen as part of the wound repair stimulant programme Apligraf(r) and he was later instrumental in its development, manufacture and methods of shipping. He is a principal inventor on several patents related to various regenerative medicines. Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.

### Contact:

Intercytex, Innovation House, Crewe Road, Manchester M23 9QR United Kingdom

T +44 (0)161 904 4500 F +44 (0)161 904 4510 [mail@intercytix.com](mailto:mail@intercytix.com) [www.intercytix.com](http://www.intercytix.com)